Taysha Gene Therapies (TSHA)

What Moves the Stock

1. 01Clinical trial data readouts for lead programs TSHA-102 (Rett syndrome), TSHA-120 (GAN), and TSHA-118 (CLN1) - interim safety/efficacy results drive 30-50% single-day moves
2. 02FDA regulatory interactions - IND clearances, Fast Track/Orphan Drug designations, breakthrough therapy status, and BLA filing timelines
3. 03Cash runway announcements - equity raises, debt financings, or partnership deals that extend operational runway beyond 12-18 months trigger valuation resets
4. 04Competitive developments in AAV gene therapy space - safety signals from competitors (liver toxicity, immune responses) or rival program failures/successes in CNS indications
5. 05Manufacturing scale-up milestones and CMC readiness for commercial production
6. 06No current revenue - pre-commercial stage
7. 07Future potential: Commercial product sales from approved gene therapies (one-time curative treatments priced $1-3M per patient)
8. 08Potential licensing or partnership revenue from platform technology

TSHA Chart

My Notes

• growth/speculative - Attracts biotech-specialized hedge funds, venture capital crossover funds…
• High sensitivity to interest rates through multiple channels: (1) Valuation - biotech stocks trade on discounted future cash flows 5-10…
• Watch on earnings: Clinical trial milestone announcements - patient enrollment completion, interim data readout dates, and topline results for TSHA-102, TSHA-120, TSHA-118, Quarterly cash burn rate and ending cash balance - track against 18-month runway threshold that typically triggers equity raises, FDA Fast Track and Breakthrough Therapy designation decisions - accelerate development timelines by 12-18 months.